|
Oct 29
|
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
|
|
Oct 27
|
Why compounders and telehealth providers are undeterred by the potential end of the weight-loss drug shortage
|
|
Oct 17
|
3 US Growth Companies With Significant Insider Ownership
|
|
Oct 16
|
Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.
|
|
Oct 15
|
Walgreens closing 1,200 stores over next 3 years, 800 more under evaluation
|
|
Oct 15
|
Do Its Financials Have Any Role To Play In Driving Hims & Hers Health, Inc.'s (NYSE:HIMS) Stock Up Recently?
|
|
Oct 14
|
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
|
|
Oct 14
|
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
|
|
Oct 14
|
Hims & Hers surges as FDA mulls over compounded drugs limit
|
|
Oct 10
|
WeightWatchers stock soars, but its cheap Wegovy knockoff 'is not a sustainable long-term business model'
|
|
Oct 4
|
Hims & Hers Health Set to Join S&P SmallCap 600
|
|
Oct 4
|
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
|
|
Oct 3
|
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
|
|
Oct 3
|
Stocks to Watch Thursday: Levi Strauss, Hims & Hers, Constellation Brands, Nvidia
|
|
Oct 3
|
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
|
|
Jul 31
|
Hims & Hers Health Stock Flashing Buy Signal Before Earnings
|
|
Jun 27
|
Heard on the Street Wednesday Recap: Land of the Rising Sum
|
|
Jun 26
|
The War Over Cheaper Ozempic Won’t End Well for Some Investors
|
|
Jun 13
|
Explore These 3 US Growth Companies With High Insider Ownership
|
|
May 20
|
Investors await Nvidia earnings, commodities on the rise: Morning Brief
|